Source:http://linkedlifedata.com/resource/pubmed/id/18384825
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2008-4-14
|
pubmed:abstractText |
The present case-control study evaluates the role of the progesterone receptor (PR) polymorphism known as PROGINS as a risk factor for ovarian cancer development and investigates the association between these genetic variants and clinical/pathologic variables of ovarian cancer. PROGINS polymorphism was examined, by polymerase chain reaction, in a total of 80 patients with ovarian cancer and 282 control subjects. The frequencies of PROGINS polymorphism T1/T1, T1/T2, and T2/T2 were 71.3, 15.0 and 13.8% in ovarian cancer patients and 78.37, 21.63 and 0% in controls, respectively. The chi(2)-test showed a higher incidence of the T2/T2 genotype (P=0.001) in the ovarian cancer group. In addition, women carrying a mutated allele (T2) showed approximately 2.2 times higher risk of ovarian cancer development as compared to women who have a variant allele (odds ratio (OR)=2.2; 95% CI=1.80-3.54). Regarding the clinical and pathologic findings observed within the cancer group, there was a significant correlation between PROGINS polymorphism and patients with a familial history (chi(2)=6.776; P=0.009; Fischer exact test, P=0.01). In this regard, patients with familial antecedents have a 4.7 times higher likelihood to have at least one risk allele (T2) as compared with patients without familial antecedents (OR=4.69; 95% CI=1.38-15.87). No correlations were observed among the other variables. These data suggest that the PROGINS polymorphism T2/T2 genotype might be associated with an increased risk of ovarian cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0039-128X
|
pubmed:author |
pubmed-author:BaracatEdmundo CEC,
pubmed-author:GonçalvesWagner JWJ,
pubmed-author:JunqueiraMichele GMG,
pubmed-author:LeiteDaniela BDB,
pubmed-author:LopesLuiz A FLA,
pubmed-author:Massad-CostaAna MAM,
pubmed-author:NicolauSergio MSM,
pubmed-author:da SilvaIsmael D C GID,
pubmed-author:de CarvalhoCristina VCV
|
pubmed:issnType |
Print
|
pubmed:volume |
73
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
676-80
|
pubmed:meshHeading |
pubmed-meshheading:18384825-Adult,
pubmed-meshheading:18384825-Aged,
pubmed-meshheading:18384825-Case-Control Studies,
pubmed-meshheading:18384825-Female,
pubmed-meshheading:18384825-Genetic Predisposition to Disease,
pubmed-meshheading:18384825-Humans,
pubmed-meshheading:18384825-Middle Aged,
pubmed-meshheading:18384825-Ovarian Neoplasms,
pubmed-meshheading:18384825-Polymorphism, Genetic,
pubmed-meshheading:18384825-Receptors, Progesterone,
pubmed-meshheading:18384825-Risk Factors
|
pubmed:year |
2008
|
pubmed:articleTitle |
Progesterone receptor (PROGINS) polymorphism and the risk of ovarian cancer.
|
pubmed:affiliation |
Molecular Gynecology Laboratory, Department of Gynecology, Federal University of São Paulo (UNIFESP-EPM), Brazil. dani.gineco@epm.br
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|